Abstract
Although the number of cutaneous squamous cell carcinoma (cSCC) cases is increasing, the effectiveness of systemic therapy for the treatment of advanced cSCC is limited. Since cSCC possesses a high tumor mutation burden (TMB) compared to other cancer species, and since high TMB correlated with increased neoantigens and the efficacy of anti-PD1 antibodies (Abs) in various cancers, cSCC could be a target for anti-PD1 Abs monotherapy. In this report, we describe a case of unresectable recurrent cSCC of the scalp with meningeal invasion, but highly expressed programmed death-ligand 1 (PD-L1), treated with nivolumab monotherapy.
Original language | English |
---|---|
Article number | e13672 |
Journal | Dermatologic Therapy |
Volume | 33 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2020 Jul 1 |
Keywords
- PD-1
- PD-L1
- cutaneous SCC
- immunotherapy
- nivolumab
ASJC Scopus subject areas
- Dermatology